Over the weekend, the Food and Drug Administration approved Leqembi, the Alzheimer’s treatment from Eisai and Biogen, for monthly dosing maintenance after patients use it biweekly for 18 months.

Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), opens new tab Alzheimer's ...

Lake Havasu and the London Bridge are uniquely Arizona road trip destinations. Here's why it's worth the drive and what to ...

Japanese drugmaker Eisai Co. Ltd. said on Monday it had submitted a marketing authorization application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Credit: Chinnapong/Shutterstock. The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen‘s Leqembi (lecanemab-irmb) for maintenance ...

Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing regimen for Leqembi (lecanemab). Already approved ...

Lake’s spokesperson, Alex Nicoll, told The Arizona Republic, “Kari Lake is not running for office in Arizona or anywhere else. She’s going to D.C. to lead the Voice of America and help ...

1 Day ESAIY -2.12% DJIA -0.31% S&P 500 -0.47% Health Care/Life Sciences 0.39% ...

A Mega Millions ticket sold on Jan. 17 was worth $112 million, making it the second-largest jackpot in Arizona's history and the largest prize ever won with a ticket purchased online, according to ...

At close: January 29 at 3:58:33 PM EST ...